The field of personalized medicine is undergoing a transformative shift through the integration of multi-omics data, which mainly encompasses genomics, transcriptomics, proteomics, and metabolomics. This synergy allows for a comprehensive understanding of individual health by analyzing genetic, molecular, and biochemical profiles. The generation and integration of multi-omics data enable more precise and tailored therapeutic strategies, improving the efficacy of treatments and reducing adverse effects. However, several challenges hinder the full realization of personalized medicine. Key hurdles include the complexity of data integration across different omics layers, the need for advanced computational tools, and the high cost of comprehensive data generation. Additionally, issues related to data privacy, standardization, and the need for robust validation in diverse populations remain significant obstacles. Looking ahead, the future of personalized medicine promises advancements in technology and methodologies that will address these challenges. Emerging innovations in data analytics, machine learning, and high-throughput sequencing are expected to enhance the integration of multi-omics data, making personalized medicine more accessible and effective. Collaborative efforts among researchers, clinicians, and industry stakeholders are crucial to overcoming these hurdles and fully harnessing the potential of multi-omics for individualized healthcare.

Cancer remains a leading global health challenge, with conventional diagnostic and treatment methods often lacking precision and adaptability. This review explores transformative advancements that are reshaping oncology by addressing these limitations. It begins with an overview of cancer’s complexity, emphasizing the shortcomings of conventional tools such as imaging and chemotherapy, which frequently fail to deliver targeted care. The discussion then shifts to biomarkers, which represent a groundbreaking frontier in early detection, enabling the identification of unique biological signatures that signal the presence of cancer with heightened sensitivity. Building on this foundation, the review examines personalized molecular therapies, which target the specific genetic and molecular vulnerabilities of tumors. These therapies not only enhance treatment efficacy but also minimize adverse effects, offering patients improved outcomes and quality of life. By integrating biomarker-driven diagnostics with tailored therapeutic strategies, a new paradigm of precision oncology emerges, bridging the gap between early detection and effective intervention. Real-world case studies highlight both successes, such as significantly improved survival rates, and persistent challenges, including accessibility and cost barriers. Looking ahead, the review outlines pathways by which to scale these innovations, emphasizing the critical need for robust infrastructure, sustained research investment, and equitable healthcare policies. It concludes by envisioning a future where biomarkers and personalized therapies converge to redefine cancer care, offering earlier detection, precise interventions, and better patient experiences. This work underscores the urgency of adopting cutting-edge approaches to overcome cancer’s persistent threats, paving the way for a more effective and humane era in oncology.

Newcastle disease (ND) is a major viral infection of poultry caused by virulent strains of avian paramyxovirus type 1, resulting in considerable global economic losses. In Ethiopia, ND outbreaks persist despite vaccination efforts, and the genetic diversity of circulating Newcastle disease virus (NDV) strains remains poorly characterized. Most previous studies have relied on partial genomic data, leaving a gap in whole-genome analysis. This study aimed to provide a comprehensive genomic investigation of NDV in Ethiopia. A cross-sectional study was conducted on 14 commercial chicken farms across five districts in central Ethiopia and parts of the Amhara region. A total of 63 pooled specimens were screened using real-time qRT-PCR. Virus isolation was performed in specific-pathogen-free embryonated chicken eggs and confirmed by qRT-PCR. For molecular characterization, the sequence-independent, single-primer amplification (SISPA) technique was applied to obtain whole-genome sequences from five NDV isolates via Oxford Nanopore sequencing Technology. Of the 63 pooled specimens, 11 (13.8%) tested positive for NDV. Whole-genome sequencing revealed two genome sizes (15,192 and 15,186 nucleotides) and confirmed virulent NDV strains with the characteristic F-gene cleavage site motif (112RRQKRF117), distinct from local vaccine strains (112GRQGR↓L117). Phylogenetic analysis showed that all isolates clustered within genotype VII, with four strains (GenBank: PV189285 – PV189288 ) exhibiting 97.24% similarity to Iranian NDV strains (accession number: ON184061 ) of sub-genotype VII.1.1. This study provides the first whole-genome insight into NDV strains circulating in Ethiopia’s poultry industry. The detection of virulent NDV in vaccinated flocks highlights the need for vaccines that are genetically and antigenically matched to circulating strains. Broader genomic surveillance across production systems is essential to guide effective ND control strategies and reduce economic losses.

Cancer remains a leading global health challenge, with conventional diagnostic and treatment methods often lacking precision and adaptability. This review explores transformative advancements that are reshaping oncology by addressing these limitations. It begins with an overview of cancer’s complexity, emphasizing the shortcomings of conventional tools such as imaging and chemotherapy, which frequently fail to deliver targeted care. The discussion then shifts to biomarkers, a groundbreaking frontier in early detection, enabling the identification of unique biological signatures that signal the presence of cancer with heightened sensitivity. Building on this foundation, the review examines personalized molecular therapies, which target the specific genetic and molecular vulnerabilities of tumors. These therapies not only enhance treatment efficacy but also minimize adverse effects, offering patients improved outcomes and quality of life. By integrating biomarker-driven diagnostics with tailored therapeutic strategies, a new paradigm of precision oncology emerges, bridging the gap between early detection and effective intervention. Real-world case studies highlight both successes such as significantly improved survival rates and persistent challenges, including accessibility and cost barriers. Looking ahead, the review outlines pathways to scale these innovations, emphasizing the critical need for robust infrastructure, sustained research investment, and equitable healthcare policies. It concludes by envisioning a future where biomarkers and personalized therapies converge to redefine cancer care, offering earlier detection, precise interventions, and better patient experiences. This work underscores the urgency of adopting cutting-edge approaches to overcome cancer’s persistent threats, paving the way for a more effective and humane era in oncology.

The field of personalized medicine is undergoing a transformative shift through the integration of multi-omics data, which encompasses genomics, transcriptomics, proteomics, and metabolomics. This synergy allows for a comprehensive understanding of individual health by analyzing genetic, molecular, and biochemical profiles. The generation and integration of multi-omics data enable more precise and tailored therapeutic strategies, improving the efficacy of treatments and reducing adverse effects. However, several challenges hinder the full realization of personalized medicine. Key hurdles include the complexity of data integration across different omics layers, the need for advanced computational tools, and the high cost of comprehensive data generation. Additionally, issues related to data privacy, standardization, and the need for robust validation in diverse populations remain significant obstacles. Looking ahead, the future of personalized medicine promises advancements in technology and methodologies that will address these challenges. Emerging innovations in data analytics, machine learning, and high-throughput sequencing are expected to enhance the integration of multi-omics data, making personalized medicine more accessible and effective. Collaborative efforts among researchers, clinicians, and industry stakeholders are crucial to overcoming these hurdles and fully harnessing the potential of multi-omics for individualized healthcare.

Ethiopia confirmed its first Marburg virus disease (MVD) outbreak on 14 November 2025 in Jinka (Omo Valley area), where a single spillover from Rousettus aegyptiacus resulted in nine laboratory-confirmed cases and eight deaths (CFR 89%). Transmission occurred in the context of concurrent cholera and large-scale population displacement. Despite these pressures, case confirmation was achieved within 48 hours, >90% of contacts were traced, and same-day L-gene sequencing placed the isolate within the East African lineage associated with the 2024 Rwanda outbreak. This review summarizes key molecular determinants of MARV virulence including GP–NPC1 mediated entry, VP24-driven interferon antagonism, and GP-associated endothelial dysfunction and examines Ethiopia’s contrasting strengths in genomic capacity and PHEOC coordination versus persistent constraints in diagnostics, clinical readiness, and countermeasure access. We outline a feasible seven-day containment framework integrating low-cost molecular testing, remdesivir therapy, and VSV-MARV ring vaccination to prevent further spread in resource-limited settings.